
Butcher shops close as E. coli outbreak kills 12-year-old girl, hospitalizes 21 children
Signs of severe food poisoning, including bloody diarrhea, first emerged on June 12 near the city of Saint-Quentin in northern France.
In total, 22 children and one elderly person have been treated and 10 of the patients were still hospitalized as of Wednesday, according to officials in the Hauts-de-France region. The girl died on Monday, June 16.
"I would like to express my deepest sympathy and solidarity with the family of the deceased girl," Health Minister Yannick Neuder said in a post Sunday on X. "To her loved ones, I extend, on behalf of the French government, my most sincere thoughts."
Initial tests determined the outbreak was caused by E. coli likely from meat consumption, he told Radio France Internationale (RFI).
Nine of the patients developed hemolytic uremic syndrome (HUS), a rare condition caused by a certain type of E. coli bacteria, according to a news release from the local prefect's office on Wednesday.
E. coli is a type of bacterium found in the environment, foods and intestines of people and animals, according to the U.S. Centers for Disease Control and Prevention (CDC).
While most varieties of E. coli are harmless, some strains, which can be contracted through contaminated food and water, can cause severe cramps, diarrhea and vomiting.
One serious strain is Shiga toxin-producing E. coli (STEC), which can lead to HUS, typically among children and the elderly, and cause kidney failure, permanent health problems — even death.
About eight in 10 children with HUS have a STEC infection, according to the CDC. There have been 1,624 HUS cases and 38 deaths from it in the U.S. in recent decades, according to the CDC's most recent data, which spans from 1997 to 2021.
Some of the hospitalized patients in France received dialysis, which filters waste and excess fluid when the kidneys are not functioning.
"Once somebody has the symptoms of hemolytic uremic syndrome, there's really no therapy other than supportive care," said Dr. Jeffrey Kahn, the chief of pediatric infectious disease at UT Southwestern Medical Center in Dallas. "Antibiotics are not going to work. We don't have an antidote."
"The way to keep these outbreaks under wraps, or at least to halt the progression, is a robust public health system."
Kahn, who is not involved in the care of the patients in France, called HUS a "nasty" disease and said he has seen children receive kidney transplants and come into renal failure as a result of it.
It has spread in the U.S. as a result of chopped meat and apple cider, he noted.
"The way to keep these outbreaks under wraps, or at least to halt the progression, is a robust public health system," Kahn added. "The investigators are key."
Investigations by several government offices into the origins of the outbreak in France are ongoing, according to the prefect's office, and test samples from six Saint-Quentin-area butcher shops, which have been preemptively closed, are expected to open next week.
The poisoned individuals had eaten meat traced back to the six shops, according to preliminary investigations.
"As part of these investigations, all leads are being explored, analyzed and reported back to ensure that no possible source of contamination is ruled out," the prefect's office stated.
Neuder urged people not to panic.
"The idea is not to cause panic," he told RFI. "It is still possible to eat meat."
Fox News Digital reached out to the health minister's office for comment.
For more Lifestyle articles, visit foxnews.com/lifestyle
Officials reminded residents that symptoms linked to E. coli can appear within 10 days of eating contaminated food. They cautioned that meat from some of the butchers had been served at two sporting events and a school fair as recently as June 22.
They additionally warned people not to consume meat bought from those butchers after June 1, to clean their refrigerators thoroughly if they have purchased any and to prevent transmission by handwashing.
"The good news is, there's a lot we can do in the kitchen to help prevent E. coli infections and lower the risk of HUS," Jessica Gavin, a certified food and culinary scientist from California, told Fox News Digital.
"I always make sure to cook meat, especially ground beef and poultry, to at least 160 degrees Fahrenheit, wash my hands well after handling raw ingredients and keep raw and cooked foods separate to avoid cross-contamination."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
an hour ago
- Medscape
GLP-1 Receptor Agonists Improve HS in Patients With Obesity
TOPLINE: Investigators reported that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) were associated with significant improvements in clinical severity, patient-reported outcomes, and weight in patients with hidradenitis suppurativa (HS) and obesity. METHODOLOGY: The retrospective multicenter cohort study evaluated 66 adults (median age, 46 years; 58% women) with HS who received semaglutide, dulaglutide, or liraglutide for at least 3 months, using data from eight French hospitals, between 2017 and 2024. Their median BMI was 39.4, and 86% of patients had diabetes; 45%, 32%, and 23% of patients had Hurley stages I, II, and III disease, respectively. Outcomes included HS-Physician's Global Assessment (HS-PGA), flare frequency, Numerical Rating Scale (NRS)-Pain, NRS-Suppuration, Dermatology Life Quality Index (DLQI), and BMI at 6 months. Median follow-up was 18.5 months. TAKEAWAY: At 6 months, 54% of patients had achieved at least one-point reduction in HS-PGA and 12% of patients demonstrated at least two-point reduction; flares were reduced in 60% patients. NRS-Pain scores decreased in 52% of patients, NRS-Suppuration scores decreased in 53% patients, and improved quality of life, based on DLQI scores, was observed in 50% patients at 6 months. Among 34 patients with stable HS treatment, all outcome measures showed statistically significant improvements at 6 months (P < .001). Median BMI decreased from 39.4 to 37.2 at 6 months. IN PRACTICE: 'GLP-1 RAs offer promise for patients with HS and obesity and potentially for patients without obesity through immunological effects,' the study authors wrote. 'Randomized clinical trials are warranted to confirm the role of GLP-1 RAs in HS management,' they added. SOURCE: The study was led by Louise Gouvrion, MD, Department of Dermatology, Rennes University Hospital in Rennes, France, and was published online on August 13 in JAMA Dermatology. LIMITATIONS: The retrospective design, concurrent use of diverse HS therapies, potential selection bias, and absence of glycemic and inflammatory biomarker data limit causal inference. DISCLOSURES: The authors did not disclose any funding information. Several authors reported receiving personal fees, conference invitations, nonfinancial support from AbbVie, Almirall, Amgen, Bristol Myers Squibb, Lilly, Janssen, LEO Pharma, MSD, Novartis, UCB, and others. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.


Medscape
an hour ago
- Medscape
Teen Suicide, Binge Drinking Decline, New National Data Show
The use of cocaine, alcohol, and prescription opioids in the US has declined over the last 4 years, data from the 2024 National Survey on Drug Use and Health showed. Among adolescents aged 12-17 years, suicidal ideation and attempts declined. Nearly 1 in 5 reported moderate or severe symptoms of generalized anxiety disorder. This is the first time this outcome has been included in the survey. The percentage of those aged 12 years or above with a drug use disorder in the past year increased from 8.7% in 2021 to 9.8% in 2024 whereas those with a past-year alcohol use disorder decreased from 10.6% to 9.7% over the same time period. The data consist of self-reported surveys from nearly 70,000 people aged 12 years or above across the country and details trends of mental health conditions and substance use change. 'These data are incredibly valuable to researchers, clinicians, policymakers, and others, allowing for greater understanding of the nation's behavioral health, and to help inform actions in support of President Trump's vision to Make America Healthy Again [MAHA],' said Substance Abuse and Mental Health Services Administration (SAMHSA) Principal Deputy Assistant Secretary Art Kleinschmidt, PhD, MBA, LPC, LAC, in the news release. The report was published online on July 28. Marijuana, Hallucinogen Use Rising Among substances included in the survey, alcohol was used most often, with 46.6% reporting usage in the previous month. In 2024, 134.3 million people reported drinking alcohol in the month prior to completing the survey, a decline of 400,000 from 2023. The number of adults binge drinking in the prior month also dropped from 45.6% in 2023 to 43.1% in 2024. Among people aged 12 years or older, 63.7 million people reported past month use of tobacco products or vaped nicotine. Among adolescents aged 12-17 years who reported tobacco or nicotine use, 71.5% consumed nicotine solely by vaping. From 2021 to 2024, marijuana consumption in the overall cohort rose from 19.0% to 22.3% and hallucinogen use increased by roughly 1%. Over the past year, 1 in 4 Americans reported using an illicit drug, including 4.3 million who used cocaine (0.2% decrease from 2021) and 7.6 million who misused prescription opioids (0.4% decrease from 2021). There was no change in rates of suicidal ideation or attempts among adults overall during the study period. However, the rate of attempts increased by 0.4% among those aged 50 years or older, or an increase of roughly 500,000 people. Attempted suicides among teens decreased from 3.6% to 2.7%. About 1 in 5 people who were identified as needing substance abuse treatment received that treatment in the year prior to the survey. Among the 61.5 million adults with any mental illness, over half received mental health treatment in the past year. The findings come after months of federal budget cuts; earlier this year, an alliance of professional mental health organizations spoke out about the dangers of such losses to SAMSHA. So far, a third of the agency's staff has been cut and $1 billion withdrawn from its operating budget. 'The reality is we are facing unique addiction and mental health challenges in our country…By addressing mental health and addiction head-on we can make real, tangible progress in achieving our MAHA goals and realize a future where individuals, families, and communities are healthy and thriving,' Kleinschmidt said in an accompanying release.
Yahoo
2 hours ago
- Yahoo
Elevance Health, Inc. (ELV) Reports Q2 2025 Results; Mizuho Maintains ‘Buy' Rating With $342 PT
With a low price-to-earnings multiple and a significant presence in Seth Klarman's investment portfolio, Elevance Health, Inc. (NYSE:ELV) earns a spot on our list of the 12 Cheap Value Stocks to Buy Now According to Seth Klarman. Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements. On July 17, 2025, Elevance Health, Inc. (NYSE:ELV) released its Q2 2025 results. The company posted adjusted EPS of $8.84, slightly missing expectations of $8.91. Increased medical cost trends in ACA, along with slower Medicaid rate recovery softening margins. Yet, the higher premium yields and acquisitions resulted in a $49.4 billion revenue, an increase of 14% YoY. Meanwhile, the company's operating cash flow reached $2.1 billion. Declines in Medicaid and ACA enrollment resulted in a decrease in the Membership segment, taking it to 45.6 million. Looking ahead, Elevance Health, Inc. (NYSE:ELV) reduced its full-year EPS guidance to $30, driven by cost pressures. However, it reaffirmed its strategies to stabilize margins with disciplined pricing, AI-enabled care management, and Carelon's expanding value-based and pharmacy services. Despite the reduction in 2025 guidance, Mizuho maintained its 'Buy' rating on Elevance Health, Inc. (NYSE:ELV) with a $342 price target. The analyst's optimism is driven by the company's growth potential in Carelon and strong execution in Medicare Advantage. Elevance Health, Inc. (NYSE:ELV) is a health insurance provider, offering integrated medical, pharmacy, and care delivery solutions. It is included in our list of cheap value stocks to buy. While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best AI Stocks to Buy Under $3 and Bill Ackman Stock Portfolio: Top 10 Stock Picks. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data